Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

Tafinlar receives EMA authorisation for treatment of metastatic melanoma

GlaxoSmithKline has been granted marketing authorisation by the European Medicines Agency for Tafinlar® (dabrafenib) in monotherapy for the treatment of adult patients with melanoma that cannot be removed by surgery or that has spread to other parts of the body with a mutated BRAF protein.

GlaxoSmithKline has been granted marketing authorisation by the European Medicines Agency for Tafinlar® (dabrafenib) in monotherapy for the treatment of adult patients with melanoma that cannot be removed by surgery (unresectable) or that has spread to other parts of the body (metastatic) with a mutated BRAF protein. Melanoma is the most serious type of skin cancer and causes 75-80% of skin cancer-related deaths. In the UK, melanoma affects about 12,800 people each year The number of people getting melanoma now is more than four times higher than it was 30 years ago, and the incidence is steadily rising with age. “Dabrafenib

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy